Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin and Envafolimab with Radiochemotherapy for Stage III Squamous NSCLC
NCT06279754Phase 2Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of endostar, envafolimab in squamous cell carcinoma of the lung (SCCL), sponsored by Xinxiang Medical University First Affiliated Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
endostarenvafolimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06279754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279754.